Table 1.
In vitro antifungal susceptibility of the Candida tropicalis isolates characterized in this study.
| Isolate no. | Origin | Date of recovery | CLSI MICs (μg/mL)a |
Sensititre YeastOne MICs (μg/mL)a |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMB | FLC | ITC | KTC | PSC | VRC | CAS | AMB | 5FC | FLC | ITC | PSC | VRC | ANF | CAS | MCF | |||
| 1 | Urine | Nov. 12, 2010 | 0.5 | 0.125 | 0.031 | 0.004 | 0.063 | 0.016 | 0.125 | 1 | <0.06 | 4 | 0.5 | 0.25 | 0.25 | <0.015 | 0.015 | 0.015 |
| 2 | Urine | May 5, 2011 | 0.5 | 0.125 | 0.016 | 0.004 | 0.031 | 0.016 | 0.063 | 1 | <0.06 | 1 | 0.125 | 0.125 | 0.06 | 0.03 | 0.03 | 0.015 |
| 3 | Urine | Jun. 30, 2011 | 0.5 | 0.125 | 0.016 | 0.004 | 0.063 | 0.016 | 0.125 | 1 | <0.06 | 1 | 0.125 | 0.06 | 0.06 | <0.015 | 0.03 | 0.015 |
| 4 | Urine | Oct. 20, 2011 | 0.5 | 0.125 | 0.031 | 0.004 | 0.031 | 0.016 | 0.125 | 0.5 | <0.06 | 0.5 | 0.06 | 0.03 | 0.03 | 0.06 | 0.03 | 0.015 |
| 5 | Urine | Apr. 12, 2012 | 0.5 | >64 | >16 | 8 | >16 | >16 | 0.063 | 0.5 | <0.06 | >256 | >16 | >8 | >8 | 0.03 | 0.06 | 0.015 |
| 6 | Urine | May 23, 2012 | 0.5 | >64 | >16 | 16 | >16 | >16 | 0.25 | 1 | <0.06 | >256 | >16 | >8 | >8 | 0.06 | 0.06 | 0.03 |
| 7 | Urine | Jun. 7, 2012 | 0.5 | >64 | >16 | >16 | >16 | >16 | 0.125 | 1 | <0.06 | >256 | >16 | >8 | >8 | 0.125 | 0.06 | 0.03 |
| 8 | Bladder calculus | Jun. 11, 2012 | 0.5 | >64 | >16 | >16 | >16 | >16 | 0.25 | 1 | <0.06 | >256 | >16 | >8 | >8 | 0.06 | 0.06 | 0.03 |
a
Minimum inhibitory concentrations (MICs) were determined after 24 h of incubation at 35 °C. Antifungals tested: 5FC, flucytosine; AMB, amphotericin B; ANF, anidulafungin; CAS, caspofungin; FLC, fluconazole; ITC, itraconazole,; KTC, ketoconazole; MCF, micafungin; PSC, posaconazole; VRC, voriconazole.